SCHEMBL6509924

SCHEMBL6509924

CCc1[nH]nc2c1c(=O)[nH]c1ccc(Cl)cc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 7/20 0.70
SIRT1 Q96EB6 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CDC25A P30304 1/20 0.42
CDC25C P30307 1/20 0.42
LMNA P02545 1/20 0.42
CSF1R P07333 3/20 0.42
PTGES O14684 1/20 0.42
KIT P10721 1/20 0.42
FLT3 P36888 1/20 0.42
CYP1A2 P05177 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
GRIN2D O15399 2/20 0.41
GRIN3B O60391 2/20 0.41
GRIN1 Q05586 2/20 0.41
GRIN2A Q12879 2/20 0.41
GRIN2B Q13224 2/20 0.41
GRIN2C Q14957 2/20 0.41
GRIN3A Q8TCU5 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6513915 0.85 CHEK1 (0.60) CHEK1SIRT1ADORA3CDC25ACDC25C
SCHEMBL6507557 0.84 CHEK1 (0.62) CHEK1ADORA3CDC25ACDC25CLMNA
SCHEMBL6515387 0.84 CHEK1 (0.59) CHEK1SIRT1ADORA3CDC25ACDC25C
SCHEMBL6507585 0.82 CHEK1 (1.00) CHEK1ADORA3CDC25ACDC25CLMNA
SCHEMBL6507672 0.82 CHEK1 (0.60) CHEK1SIRT1ADORA3CDC25ACDC25C
SCHEMBL6513239 0.77 CHEK1 (0.53) CHEK1LMNAHPGDPARP1
SCHEMBL6509557 0.77 CHEK1 (0.53) CHEK1SIRT1ADORA3CSF1RPTGES
SCHEMBL6509456 0.75 CHEK1 (0.51) CHEK1SIRT1ADORA3CSF1RPTGES
SCHEMBL731128 0.72 CHEK1 (0.55) CHEK1ADORA3LMNACYP1A2HPGD
SCHEMBL10063705 0.69 SIRT1 (0.54) SIRT1LMNACYP1A2GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 CHEK1 3/4885SIRT1 3496/4885ADORA3 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.